ChemBioChem · 2008 · 45 citations · 37 references
PharmacyOncologyPharmaceuticsApoptosisDrug DeliveryTargeted Drug DeliveryAnticancer Prodrug DesignApoptosis In CancerCancer Drug DeliveryLigand-mediated TargetingPeptide DeliveryPeptide ProdrugsApoptosis TargetingAssayPeptide ConjugatesPeptide-drug ConjugatesRgd PeptidesTherapeutic PeptidesTumor-homing PeptidesTumor-targeting Peptides
We report herein the synthesis and in vitro assay of new, multimeric RGD-peptide conjugates for cell-targeted drug delivery. We generated a peptide scaffold comprising two functional domains, one a tumour blood vessel "homing" motif and the other a programmed cell-death-inducing peptide sequence. RGD peptides were selected to direct the molecular conjugate to alpha(V)beta(3) integrin-containing tumour cells. The pro-apoptotic (Lys-Leu-Ala-Lys-Leu-Ala-Lys)(2) peptide was found to be nontoxic outside cells, but toxic when internalized into targeted cells as it disrupted the mitochondrial membrane. The synthesis of these targeted pro-apoptotic conjugates was carried out by assembling three different units (that is, scaffold, RGD units and pro-apoptotic peptide) through chemoselective ligations. We show that one compound displays significant biological effect in alpha(V)beta(3) integrin-containing tumour cells.
37
Anti-cancer activity of targeted pro-apoptotic peptides
H. Michael Ellerby, Wadih Arap, Lisa Ellerby et al. · Nature Medicine · 1999 · 930 citations
Roland Haubner, Rainer Gratias, Beate Diefenbach et al. · Journal of the American Chemical Society · 1996 · 580 citations